A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia

This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.

Inclusion Criteria: * Patients with hemophilia and liver cirrhosis caused by HIV/HCV co-infection who meet both of the following criteria: 1. Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at \ 1. Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening. 2. Abdominal CT showing changes in liver morphology and/or findings suggestive of portal hypertension. * Patients with an Eastern Cooperative Oncology Group Performance Status of 0-2. Exclusion Criteria: * Patients with liver cirrhosis caused by etiologies other than HCV or of unknown etiology. * Patients with esophageal or gastric varices judged by endoscopic examination at screening to require treatment. * Patients with current malignancy or a history of malignancy within 3 years before registration. * Patients who have undergone liver transplantation or other organ transplantation, including bone marrow transplantation. * Patients with active AIDS-defining disease requiring treatment. -